In-Vivo experiment designed to assess clinical efficacy targeting N/A in Germ-free 5xFAD mice with SCFA supplementation. Primary outcome: Amyloid plaque burden and TREM2 microglial expression
Investigate whether SCFA (butyrate/acetate) supplementation via GPR43 (FFAR2) activation restores TREM2-dependent microglial homeostatic function and reduces amyloid plaque burden in germ-free 5xFAD mouse model of AD.
in-vivo
SCFA supplementation increases TREM2 expression and reduces amyloid plaque load by >30% in germ-free 5xFAD mice, with reversal upon GPR43 blockade.
Amyloid plaque burden (Congo red/IHC), TREM2 expression (RT-qPCR, flow cytometry); threshold: p < 0.05 vs. vehicle.
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.